Literature DB >> 1879992

Influence of acetyl-L-carnitine infusion on haemodynamic parameters and survival of circulatory-shock patients.

A Gasparetto1, G G Corbucci, R A De Blasi, M Antonelli, E Bagiella, S D'Iddio, C Trevisani.   

Abstract

The clinical use of acetyl carnitine in circulatory shock has its theoretical basis in the ability of this molecule to restore enzyme activity inhibited by hypoxia, acting as an acetyl donor. Moreover the action of carnitine on an injured myocardium encouraged us to examine the clinical effect of this drug during heart failure. A double-blind clinical study was performed in ten Italian intensive care units on 115 patients with septic, cardiac of traumatic shock, by using acetyl-L-carnitine infusion for 12 hours, with a previous single bolus intravenously. The results showed a good response to the drug in terms of blood oxygenation during the course of sepsis and heart failure. The heart rate as well as right atrial pressure decreased significantly in patients with cardiogenic shock. In septic patients systolic and mean arterial pressures increased also. The present data suggests the use of acetyl-L-carnitine as an adjuvant to the commonly used therapy in hypoxic conditions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1879992

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Res        ISSN: 0251-1649


  5 in total

1.  Preliminary safety and efficacy of L-carnitine infusion for the treatment of vasopressor-dependent septic shock: a randomized control trial.

Authors:  Michael A Puskarich; Jeffrey A Kline; Virginia Krabill; Heather Claremont; Alan E Jones
Journal:  JPEN J Parenter Enteral Nutr       Date:  2013-07-12       Impact factor: 4.016

2.  Pharmacometabolomics of l-carnitine treatment response phenotypes in patients with septic shock.

Authors:  Michael A Puskarich; Michael A Finkel; Alla Karnovsky; Alan E Jones; Julie Trexel; Brooke N Harris; Kathleen A Stringer
Journal:  Ann Am Thorac Soc       Date:  2015-01

Review 3.  Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders.

Authors:  Carmen Mingorance; Rosalía Rodríguez-Rodríguez; María Luisa Justo; María Alvarez de Sotomayor; María Dolores Herrera
Journal:  Vasc Health Risk Manag       Date:  2011-03-28

4.  Using l-Carnitine as a Pharmacologic Probe of the Interpatient and Metabolic Variability of Sepsis.

Authors:  Theodore S Jennaro; Michael A Puskarich; Marc R McCann; Christopher E Gillies; Manjunath P Pai; Alla Karnovsky; Charles R Evans; Alan E Jones; Kathleen A Stringer
Journal:  Pharmacotherapy       Date:  2020-08-10       Impact factor: 4.705

5.  Effect of Levocarnitine vs Placebo as an Adjunctive Treatment for Septic Shock: The Rapid Administration of Carnitine in Sepsis (RACE) Randomized Clinical Trial.

Authors:  Alan E Jones; Michael A Puskarich; Nathan I Shapiro; Faheem W Guirgis; Michael Runyon; Jason Y Adams; Robert Sherwin; Ryan Arnold; Brian W Roberts; Michael C Kurz; Henry E Wang; Jeffrey A Kline; D Mark Courtney; Stephen Trzeciak; Sarah A Sterling; Utsav Nandi; Deepti Patki; Kert Viele
Journal:  JAMA Netw Open       Date:  2018-12-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.